Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Announces Positive New Data on HER-Vaxx Cancer Vaccine Phase Ib Trial Presented at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia, 2 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase Ib study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.

The poster (abstract number 8249) was presented by Professor Ursula Wiedermann from the Medical University Vienna, the lead-inventor of the HER-Vaxx cancer vaccine and member of Imugene’s Scientific Advisory Board, together with a well known research team at the Medical University Vienna.


For further information please download PDF attached:
Download this document